Immunogenicity and Safety of HavisureTM Vaccine Developed by Human Biologicals Institute in Healthy Subjects of 12 Months to 49 Years of Age: A Phase II/III, Randomized, Single Blind, Non-Inferiority Study.
VACCINE（2023）
关键词
Havisure (TM) vaccine,Havrix (R) vaccine,Safety,Immunogenicity
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要